We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Ocular Hypertension - Pipeline Review, H2 2018

Published: August 2018
Pages: 130
Code: 22AD9220B6A732D8EC03E13C29F9DA69
Format: PDF
Publisher Global Markets Direct
From Add to basket
$ 2,000.00
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide , provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape.
Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea and bleeding at the optic nerve head. Treatment includes eye drops to reduce intraocular pressure.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide , provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ocular Hypertension (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 3, 9, 14, 2 and 9 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Ocular Hypertension (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Additonal Information

  • - The pipeline guide provides a snapshot of the global therapeutic landscape of Ocular Hypertension (Ophthalmology).
  • - The pipeline guide reviews pipeline therapeutics for Ocular Hypertension (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • - The pipeline guide reviews key companies involved in Ocular Hypertension (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • - The pipeline guide evaluates Ocular Hypertension (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • - The pipeline guide reviews latest news related to pipeline therapeutics for Ocular Hypertension (Ophthalmology)

Companies Mentioned

Aerie Pharmaceuticals Inc
Allergan Plc
Angelini Group
Can-Fite BioPharma Ltd
D. Western Therapeutics Institute Inc
Ironwood Pharmaceuticals Inc
Kowa Co Ltd
Laboratorios SALVAT SA
Laboratorios Sophia SA de CV
Lee's Pharmaceutical Holdings Ltd
Neurim Pharmaceuticals Ltd
NicOx SA
Novartis AG
Ocular Therapeutix Inc
Santen Pharmaceutical Co Ltd
Senju Pharmaceutical Co Ltd
Shire Plc
Sun Pharma Advanced Research Company Ltd
Sylentis SAU
Taejoon Pharm Co Ltd

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage. Find and recognize significant and varied types of therapeutics under development for Ocular Hypertension (Ophthalmology). Classify potential new clients or partners in the target demographic. Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. Formulate corrective measures for pipeline projects by understanding Ocular Hypertension (Ophthalmology) pipeline depth and focus of Indication therapeutics. Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the knowhow what drove them from pipeline.
Add to basket
  • Table of Contents
  • Table of Contents 2
  • Introduction 5
  • Ocular Hypertension - Overview 6
  • Ocular Hypertension - Therapeutics Development 7
  • Ocular Hypertension - Therapeutics Assessment 16
  • Ocular Hypertension - Companies Involved in Therapeutics Development 25
  • Ocular Hypertension - Drug Profiles 35
  • Ocular Hypertension - Dormant Projects 112
  • Ocular Hypertension - Discontinued Products 114
  • Ocular Hypertension - Product Development Milestones 116
  • Appendix 125
  • List of Tables
  • Number of Products under Development for Ocular Hypertension, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Products under Development by Companies, H2 2018 (Contd..2), H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Ocular Hypertension - Pipeline by Aerie Pharmaceuticals Inc, H2 2018
  • Ocular Hypertension - Pipeline by Allergan Plc, H2 2018
  • Ocular Hypertension - Pipeline by Angelini Group, H2 2018
  • Ocular Hypertension - Pipeline by Can-Fite BioPharma Ltd, H2 2018
  • Ocular Hypertension - Pipeline by D. Western Therapeutics Institute Inc, H2 2018
  • Ocular Hypertension - Pipeline by Ironwood Pharmaceuticals Inc, H2 2018
  • Ocular Hypertension - Pipeline by Kowa Co Ltd, H2 2018
  • Ocular Hypertension - Pipeline by Laboratorios SALVAT SA, H2 2018
  • Ocular Hypertension - Pipeline by Laboratorios Sophia SA de CV, H2 2018
  • Ocular Hypertension - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2018
  • Ocular Hypertension - Pipeline by Neurim Pharmaceuticals Ltd, H2 2018
  • Ocular Hypertension - Pipeline by NicOx SA, H2 2018
  • Ocular Hypertension - Pipeline by Novartis AG, H2 2018
  • Ocular Hypertension - Pipeline by Ocular Therapeutix Inc, H2 2018
  • Ocular Hypertension - Pipeline by Santen Pharmaceutical Co Ltd, H2 2018
  • Ocular Hypertension - Pipeline by Senju Pharmaceutical Co Ltd, H2 2018
  • Ocular Hypertension - Pipeline by Shire Plc, H2 2018
  • Ocular Hypertension - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2018
  • Ocular Hypertension - Pipeline by Sylentis SAU, H2 2018
  • Ocular Hypertension - Pipeline by Taejoon Pharm Co Ltd, H2 2018
  • Ocular Hypertension - Dormant Projects, H2 2018
  • Ocular Hypertension - Dormant Projects, H2 2018 (Contd..1), H2 2018
  • Ocular Hypertension - Discontinued Products, H2 2018
  • Ocular Hypertension - Discontinued Products, H2 2018 (Contd..1), H2 2018
  • List of Figures
  • Number of Products under Development for Ocular Hypertension, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products by Targets, H2 2018
  • Number of Products by Stage and Targets, H2 2018
  • Number of Products by Mechanism of Actions, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018

Keywords
;